The Menopause Market: Destigmatizing Care or Commercializing Women’s Health?

A Long-Overdue Shift

For decades, menopause was the ghost in the room of women’s healthcare—an inevitable, complex transition affecting half the population, yet too often treated with embarrassment, euphemism, or clinical disinterest. Women reporting symptoms like hot flashes, night sweats, or mood swings were told to “wait it out” or offered limited treatment options, typically centered on hormone replacement therapy (HRT), which became controversial after early 2000s studies like the Women’s Health Initiative (WHI) raised concerns over cardiovascular risks and breast cancer. (Subsequent analysis has since refined those risks.)[^1]

This gap in care created a vacuum—one now rapidly filled by the private sector. Startups like Maven, Evernow, and Hello Again offer concierge-style access to hormone therapies, vaginal care products, and telemedicine consultations. Brands like Rory (an offshoot of Ro) package menopause relief in monthly subscription boxes. Influencers and media outlets amplify the message: menopause is normal, it’s manageable, and it’s time we talk about it.

This cultural shift is undeniably positive. For too long, women suffered in silence. Today, they are equipped with information, options, and language to demand better care.

But the method of that empowerment—the commercial marketplace—raises a different set of concerns.

Healthcare or Health Retail?

At its best, the menopause movement is correcting decades of medical neglect. At its worst, it’s a masterclass in health commodification. The distinction between health education and health marketing grows blurrier by the day.

As wellness brands flood the space, menopause is increasingly framed not as a life stage, but as a problem to be solved—with products. And in the absence of strict regulation, the solutions vary wildly in quality and efficacy. A 2023 review by the North American Menopause Society (NAMS) found that many over-the-counter menopause supplements lacked clinical validation, yet were marketed as essential tools for symptom management.

This marketing explosion also introduces a broader issue: consumer-driven care. In bypassing traditional OB/GYN pathways, these platforms offer convenience—but may inadvertently weaken the patient-provider relationship that is foundational to personalized, evidence-based care.

The Rise of Menopause Tech

Technology plays a central role in this transformation. Telehealth platforms targeting menopause offer accessible care, often without requiring in-person exams or continuity of care. They appeal to women who are frustrated with long wait times, patronizing doctors, or a lack of menopause-literate providers.

Yet the frictionless user experience comes at a cost. Algorithms—not always regulated—may guide hormone therapy protocols. Personalized care plans can be generated from standardized online quizzes. Follow-ups may be automated. Critics argue that this reduces menopause management to a transactional model—efficient, yes, but potentially oversimplified.

Moreover, as The BMJ has warned, the pivot to direct-to-consumer digital care risks reinforcing disparities. Women without digital literacy, stable internet, or the disposable income for subscription services may be left behind—creating a menopause market that privileges the affluent and tech-savvy.

Where Are the OB/GYNs?

This shift toward consumer-first care also raises questions about the role of traditional OB/GYN medicine. In a field already overburdened and underfunded, the exodus of patients to wellness brands can be seen as both a symptom and a cause of systemic neglect.

Some OB/GYNs welcome the competition, viewing it as a necessary wake-up call to modernize practice. Others express concern that patients are being siphoned off into fragmented care systems with minimal oversight.

A 2024 editorial in Obstetrics & Gynecology warned of a “decoupling” of reproductive care—where women’s health becomes bifurcated into public clinical care and private wellness solutions, with limited cross-talk between them. As a result, critical health screenings, like bone density tests or cancer checks, may fall through the cracks when patients self-manage menopause through apps or supplements.

The Branding of Biology

Then there is the question of how menopause is being framed in public discourse. Much of the messaging, while empowering, leans toward optimization: menopause as a phase to be hacked, managed, or conquered.

Marketing emphasizes vitality, productivity, and aesthetic appeal—encouraging women to “stay sexy” and “stay young” as they age. While such narratives challenge the stereotype of the invisible, postmenopausal woman, they can also reproduce another problem: the idea that symptoms are intolerable deviations from normality, rather than natural transitions.

This isn’t new. As cultural historian Susan Bordo argued in Unbearable Weight, Western medicine has long medicalized women’s bodies under the guise of improvement. The modern menopause industry may be simply repackaging that impulse in pastel branding.

The Path Forward

To be clear, the surge in menopause awareness is a victory. It signals a growing cultural willingness to value women’s health beyond fertility. It gives women tools to advocate for themselves in a system that has often failed them.

But like all revolutions, it must be scrutinized—not just for what it empowers, but for what it replaces.

Policymakers must consider better integration of menopause care into public health frameworks, including funding for research, standardized provider training, and equitable access to HRT. Professional organizations like ACOG (American College of Obstetricians and Gynecologists) must update curricula and treatment guidelines to reflect modern understanding of menopausal health.

Meanwhile, consumers should be encouraged to ask hard questions—not just “does this product work for me?” but “who profits from this solution?” and “how is my doctor—or my app—making these recommendations?”

Because while brands can destigmatize, they cannot replace the deep, contextual care that only trained providers can offer. And while influencers can open the conversation, the conversation must extend beyond what can be purchased.

Conclusion

Menopause is no longer invisible—but that visibility comes with a price tag. Whether the new marketplace becomes a liberating force or a commodified distraction depends on how we, as patients, providers, and policymakers, choose to shape it.

The question is no longer whether menopause will be addressed—but how. And in answering that, we must be careful not to mistake accessibility for accountability, branding for biology, or disruption for depth.